Instem has agreed with the vendors of Logos (now Instem Clinical) an early settlement of the outstanding deferred consideration. This is positive news as it cleans things up and is a reflection of the strong performance of Logos since it was acquired in 2013. No changes to our forecasts at this stage and we look forward to the full year trading update in January.